EMPA-REG OUTCOME: The Cardiologist's Point of View

Son V. Pham, Robert J. Chilton

Resultado de la investigación: Articlerevisión exhaustiva

17 Citas (Scopus)

Resumen

Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.

Idioma originalEnglish (US)
Páginas (desde-hasta)S53-S58
PublicaciónAmerican Journal of Cardiology
Volumen120
N.º1
DOI
EstadoPublished - jul. 1 2017

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Huella

Profundice en los temas de investigación de 'EMPA-REG OUTCOME: The Cardiologist's Point of View'. En conjunto forman una huella única.

Citar esto